EKF Diagnostics Investor Announcements


EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.

PointMan™ shown to be a useful method for non-invasively determining plasma EGFR T790M mutation status in late stage lung cancer patients.

Sonia Nicholas, SelectScience's Clinical Editor spoke to Dr Ricardo Del Sol, Senior Lecturer at the College of Medicine, Institute of Life Science at Swansea University, UK, about using PointMan™ DNA enrichment kits and how working with EKF Diagnostics is leading to new advances in cancer diagnostics.

2nd Apr 2015

EKF Diagnostics announces that the Board of Directors have initiated a strategic review.

Audited final results for the year ended 31 December 2014. 

EKF Diagnostics subsidiary , Selah Genomics, has announced a major, four-way collaboration with Greenville Health System (GHS, North Carolina), DecisionQ Corporation (Washington DC), and BD Technologies (New Jersey). 

Major 18 month collaboration in the US using PrecisionPath to provide genetic profiles of cancer tumours. 

23rd Feb 2015

EKF Diagnostics Holdings plc will announce its preliminary results.